“Fiscal 2025 represents the strongest annual performance in Cannara Biotech’s history and reflects our ability to execute on the significant growth opportunity in front of us,” stated Zohar Krivorot, ...

"Fiscal 2025 represents the strongest annual performance in Cannara Biotech’s history and reflects our ability to execute on the significant growth opportunity in front of us,” stated Zohar Krivorot, ...

Record Fiscal 2025 Financial Performance: Record net revenues of $107.3 million, adjusted EBITDA of $28.1 million 1, net income of $13.1 million, operating cash flow of $20 million and free cash flow ...

Record Revenue: Total revenues, net of excise taxes increased to $27.3 million in Q3 2025, representing a 40% increase over the prior year period. Record Profitability: Gross profit before fair value ...

All financial results are reported in Canadian dollars, unless otherwise stated. MONTREAL, July 28, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara ...

Q1 2023 revenue of $10.3 million, an 57% increase compared to Q1 2022. Recorded Q1 2023 gross profit before fair value adjustments of $4 million, an increase of 34% compared to Q1 2022. Delivered the ...